Eli Lilly and Company is making a bold push deeper into infectious disease prevention.

 

The pharma powerhouse has announced agreements to acquire three biotech players—Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc.—in deals that expand its vaccine and immunology pipeline.

 

The move signals a strategic acceleration toward prevention-first medicine, as Lilly doubles down on technologies aimed at stopping disease before it starts rather than treating it after the fact.

 

“For 150 years, Lilly has advanced medicines to address the world's most pressing health challenges. Infectious diseases remain a major source of global morbidity, both in their acute presentation and in the downstream health consequences of primary infection.”

 

“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” said Daniel M. Skovronsky, chief scientific and product officer, and president, Lilly Research Laboratories. 

 

“Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies' platforms and teams with Lilly's global scale positions us to change that trajectory.”

 

At the center of the Curevo deal is amezosvatein, a next-generation shingles vaccine designed to improve tolerability while maintaining immune protection. In a Phase 2 head-to-head study against the current standard, it matched immune responses across primary endpoints while cutting side effects such as fatigue, chills, and injection-site pain by more than half. 

 

The company argues better tolerability could lift vaccination rates and reduce long-term complications, including growing evidence linking shingles to stroke risk and reduced dementia risk after vaccination.

 

Under the agreement, Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.

 

The acquisition of LimmaTech Biologics AG adds a strong bacterial vaccine pipeline targeting pathogens increasingly resistant to antibiotics, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. Its lead candidate, LTB-SA7, is already in Phase 1 trials against S. aureus, the leading cause of surgical-site infections. 

 

The platform focuses on generating broad immune responses by targeting toxins and superantigens, with additional programs aimed at infections linked to infertility and long-term disease burden.

 

The deal values LimmaTech at up to $780 million, including milestone payments tied to clinical and regulatory progress.

 

Meanwhile, Vaccine Company brings an early-stage but potentially transformative platform built on In Vivo Nanoparticle (IVN) technology, designed to mimic virus-like particle immune responses without complex manufacturing. 

 

Its lead preclinical program targets Epstein-Barr Virus (EBV), with a five-antigen vaccine candidate nearing Phase 1 readiness. EBV has been increasingly linked to multiple sclerosis and certain cancers, raising the stakes for a successful preventive vaccine.

 

That acquisition could be worth up to $1.55 billion, depending on clinical and commercial milestones.

 

All three transactions remain subject to standard regulatory approvals, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Lilly will finalize accounting treatment after closing, with results to be reflected in future financial reporting and guidance.